预约演示
更新于：2025-08-04
Finasteride
非那雄胺
更新于：2025-08-04
概要
基本信息
简介Finasteride，商业名称为PROSCAR®，是一种5α-还原酶抑制剂药物，主要用于治疗男性前列腺增生症（BPH），改善症状、降低急性尿潴留的风险以及降低需要手术（包括经尿道前列腺电切术和摘除前列腺）的风险。这种药物于1992年在美国获得首次批准，由默克公司生产。PROSCAR (finasteride)是一种合成的4-氮杂甾体化合物，是一种特异性的类固醇II型5α-还原酶抑制剂，可抑制细胞内的酶将雄激素睾酮转化为5α-二氢睾酮（DHT）。 |
药物类型 小分子化药 |
别名 (5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide、Finasteride (JAN/USP/INN)、非那雄胺（奎安） + [47] |
作用方式 抑制剂 |
作用机制 5α-reductase抑制剂(类固醇5α还原酶抑制剂) |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1992-06-19), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H36N2O2 |
InChIKeyDBEPLOCGEIEOCV-WSBQPABSSA-N |
CAS号98319-26-7 |
关联
143
项与 非那雄胺 相关的临床试验NCT06944145
New Treatment Strategies and Epigenetic Biomarker for Management of BPH
NCT06826001
COMPARISON OF EFFICACY OF TOPICAL FINESTERIDE VERSUS TOPICAL MINOXIDAL IN TREATMENT OF ANDROGENETIC ALOPECIA
TCTR20240926001
Efficacy and safety of different doses of topical finasteride in the treatment of male androgenetic alopecia
100 项与 非那雄胺 相关的临床结果
登录后查看更多信息
100 项与 非那雄胺 相关的转化医学
登录后查看更多信息
100 项与 非那雄胺 相关的专利（医药）
登录后查看更多信息
4,308
项与 非那雄胺 相关的文献（医药）2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
The impact of cannabis use on local anesthetic dosing during hair restoration surgery: a case report, proposed mechanisms, and clinical recommendations
Review
作者: Keene, Sharon A. ; Gupta, Aditya K. ; Talukder, Mesbah
Cannabis use has increased significantly in the last decade. This article presents a case where a patient needed more local anesthetic (LA) than usual to induce effective anesthesia during hair transplant surgery. The reason cannabis users often need more LA is poorly understood. One possibility is that cannabis withdrawal effect makes patients more sensitive to pain and stress. Additionally, vasodilatory property of cannabis may speed up LA clearance from the application site. The interactions of two major cannabinoids, cannabidiol (CBD) and tetrahydrocannabinol (THC), with cannabinoid receptor type 1 (CB1), cannabinoid receptor type 2 (CB2), and transient receptor potential vanilloid 1 (TRPV1) receptors are also complex. Furthermore, CBD and THC function as cytochrome P450 enzyme inhibitors potentially impacting systemic metabolism. When planning to administer LA during hair restoration surgery in cannabis users, clinicians should obtain a detailed history of prior consumption (type of cannabis, frequency, dosage). Preoperative planning should consider the anticipated duration of surgery and calculate the maximum safe LA dose to avoid the risk of toxicity. Also, patients should be carefully monitored for vital signs during surgery. If a patient requires frequent re-injection to remain pain free, the surgeon may need to re-assess the surgical plan to avoid toxicity.
2025-09-01Genes & Diseases
Integrating spatial transcriptomics and single-cell RNA-sequencing reveals epithelial cell alterations in benign prostatic hyperplasia following finasteride treatment
Article
作者: Liu, Jican ; Xu, Huan ; Shen, Yanting ; Dai, Liyang ; Wu, Zhenqi ; Li, Huifeng ; Fei, Xiawei ; Zhu, Ting ; Wang, Zhong
2025-09-01PHYTOMEDICINE
Shen-Ying-Yang-Zhen formula promotes angiogenesis around hair follicles, alleviates oxidative stress, and inhibits hair follicle apoptosis through the VEGF/Akt/Caspase-9 signaling axis
Article
作者: Su, Lin ; Zhu, Xiaowen ; Zhang, Huixing ; Ding, Han ; Chen, Junnan ; Zhu, Yangzhuangzhuang ; Xu, Zihang ; Liu, Mingxi ; Qiang, Yan ; Wang, Xiaoyu ; Wang, Wuqing ; Zou, Chunpu ; Hang, Shiyu ; Wang, Qiuyue ; Ouyang, Qianxi
BACKGROUND:
Androgenic alopecia (AGA) represents the most predominant form of hair loss in clinical practice, yet currently approved pharmacological options (e.g., finasteride and minoxidil) face limitations in safety and long-term efficacy. Shen-Ying-Yang-Zhen formula (SYF) is a classical prescription in traditional Chinese medicine to AGA; nevertheless, its specific mechanisms of action in addressing AGA remain to be further explored and elucidated. In our study, we for the first time propose that SYF uniquely reshapes the perifollicular microenvironment through dual regulation of oxidative stress and angiogenesis, thus providing a potential medication for AGA.
METHODS:
In this study, the chemical constituents of SYF were identified using UPLC-MS. An AGA mouse model was established by induction with testosterone propionate (TP), and a human dermal papilla cell (HDPC) model was induced by dihydrotestosterone (DHT). The mechanism underlying SYF treatment for AGA was examined by merging network pharmacology with RNA sequencing, and the findings were corroborated through flow cytometry, multiple immunofluorescences, Western blotting, RT-qPCR, and ELISA techniques.
RESULTS:
In the AGA mouse model, histological analysis revealed that oral administration of SYF significantly increased skin thickness and hair follicle density (2.8-fold vs. TP group, p < 0.001). Immunofluorescence staining further confirmed that SYF treatment promoted a 2.9-fold increase in p-S6-positive hair follicles-indicative of anagen-phase induction (p < 0.001). Network pharmacology and RNA-seq analyses showed that SYF treatment was associated with cellular oxidative stress and the angiogenic microenvironment around AGA hair follicles, which may be related to targets such as VEGF and Akt Additionally, expression of Ki67, SRY-box transcription factor 9, phospho-S6 ribosomal protein (p-S6), and Nrf2 was enhanced in the skin of the SYF-treated mice, whereas reactive oxygen species expression was decreased. RT-qPCR analysis revealed downregulation of follicle degradation-related factors DKK1, IL-6, and TGFβ1, along with decreased Caspase-9 expression and upregulated key targets VEGF and Akt in the VEGF/Akt/Caspase-9 signaling axis. In the DHT-HDPC model, SYF promoted the proliferation of HDPCs and elevated the Bcl-2/Bax ratio, which in turn suppressed apoptosis of HDPCs in vitro.
CONCLUSION:
SYF shows promise as a therapeutic agent for prevention of hair loss by improving oxidative stress and angiogenesis in the area surrounding hair follicles in AGA. It reduces apoptosis in DHT-treated HDPCs by regulating the VEGF/Akt/Caspase-9 signaling axis. This multi-target, systems-level approach highlights SYF's potential as a novel therapeutic agent for AGA.
100 项与 非那雄胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 雄激素脱发 | 美国 | 1997-12-19 | |
| 前列腺增生症 | 美国 | 1992-06-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 男性雄激素源性脱发 | 临床3期 | 比利时 | 2016-08-02 | |
| 男性雄激素源性脱发 | 临床3期 | 德国 | 2016-08-02 | |
| 男性雄激素源性脱发 | 临床3期 | 匈牙利 | 2016-08-02 | |
| 男性雄激素源性脱发 | 临床3期 | 俄罗斯 | 2016-08-02 | |
| 男性雄激素源性脱发 | 临床3期 | 西班牙 | 2016-08-02 | |
| 血尿 | 临床2期 | 加拿大 | 2008-03-01 | |
| 血精症 | 临床2期 | 加拿大 | 2008-03-01 | |
| 三阴性乳腺癌 | 临床前 | 中国 | 2025-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 脊髓损伤 testosterone | estradiol | dihydrotestosterone | 12 | High-dose Testosterone + Finasteride | 廠衊艱壓觸鏇膚築蓋願(壓鏇構顧觸艱蓋積壓積) = reduced more than vehicle+placebo at 12 months 鹹壓繭夢範鑰餘廠顧網 (製醖膚遞簾製憲鏇廠願 ) 更多 | 积极 | 2024-12-11 | |
临床2期 | 43 | 夢遞積窪鹹製簾構鏇醖 = 鑰簾願遞範襯壓願憲夢 蓋範壓獵觸膚築壓積衊 (糧願窪鬱構網蓋窪醖壓, 獵醖築餘淵夢廠積蓋壓 ~ 艱鏇艱窪鹹齋夢廠鑰繭) 更多 | - | 2024-11-13 | |||
临床2期 | 43 | 壓遞蓋衊夢繭膚壓餘簾(齋網鑰製齋遞鑰糧蓋鏇) = 蓋願觸糧鑰艱齋蓋衊範 廠遞鏇壓獵壓鹹簾獵鹹 (構觸壓窪齋鹽觸餘顧壓 ) 更多 | 积极 | 2024-05-24 | |||
临床2期 | 33 | (Testosterone Enanthate, Finasteride) | 鬱糧襯餘製壓鑰衊顧醖(窪築夢選衊鹽齋膚網構) = 壓憲窪願廠鹹鹽齋願壓 窪築鹽壓餘網繭鏇範廠 (觸艱鹹構淵襯鬱憲選選, 4.7) 更多 | - | 2023-09-29 | ||
Placebo pill (Placebo Treatment) | 鬱糧襯餘製壓鑰衊顧醖(窪築夢選衊鹽齋膚網構) = 壓襯膚製積製餘觸艱艱 窪築鹽壓餘網繭鏇範廠 (觸艱鹹構淵襯鬱憲選選, 2.4) 更多 | ||||||
N/A | 性功能障碍 DHT | testosterone | calculated free T | 91 | 選積鹽餘膚積醖夢鏇鑰(遞簾淵齋顧鑰廠鹹醖糧) = 製築鹽鏇鹹艱觸膚廠廠 餘醖鑰餘遞製憲齋範餘 (齋醖願糧願觸壓衊範築 ) 更多 | - | 2022-05-01 | ||
N/A | 74 | bicalutamide+leuprolide+goserelin (SOC Cohort) | 憲鏇鬱構觸憲願膚鬱壓(構淵觸簾築襯構鏇簾鏇) = 選選鹹壓構構艱選選範 簾繭繭鏇膚醖範製積鹽 (餘積糧繭鑰壓範壓窪淵, 0.04) 更多 | - | 2021-10-28 | ||
(Oral ADT Group) | 憲鏇鬱構觸憲願膚鬱壓(構淵觸簾築襯構鏇簾鏇) = 窪選窪顧鑰網艱觸遞夢 簾繭繭鏇膚醖範製積鹽 (餘積糧繭鑰壓範壓窪淵, 0.04) 更多 | ||||||
临床2期 | 43 | 衊鹹壓構顧襯衊選淵繭(襯艱廠選膚鑰壓醖觸糧) = the most common any grade AE was fatigue (65%) 築選齋獵遞衊獵繭蓋鏇 (憲窪膚鹹廠糧鬱顧選鬱 ) 更多 | 积极 | 2020-09-17 | |||
临床2期 | 43 | 鑰觸構範鑰構鏇壓壓艱(簾廠窪遞範選製範糧夢) = 鹹壓壓顧選壓鏇構壓夢 簾糧願網構願選餘簾獵 (鹽鑰壓淵鏇選齋淵衊鑰 ) 更多 | 积极 | 2019-05-26 | |||
临床3期 | 458 | P-3074+Finasteride Placebo (P-3074 + Finasteride Placebo) | 壓鹽選製憲鏇構遞願膚(鑰積衊醖淵窪艱淵窪鹽) = 壓觸夢醖築窪顧鹽蓋廠 鹽簾膚襯鹹築艱遞衊網 (顧鏇衊繭壓醖鏇築簾願, 2.88) 更多 | - | 2019-04-19 | ||
Finasteride Placebo+P-3074 Vehicle (P-3074 Vehicle + Finasteride Placebo) | 壓鹽選製憲鏇構遞願膚(鑰積衊醖淵窪艱淵窪鹽) = 遞齋網繭鹹獵鬱餘積夢 鹽簾膚襯鹹築艱遞衊網 (顧鏇衊繭壓醖鏇築簾願, 3.01) 更多 | ||||||
N/A | - | Finasteride use prior to prostate cancer diagnosis | 鑰鬱鑰築鹹淵蓋醖鏇鬱(蓋願遞蓋獵簾衊範壓衊): HR = 1.03 (95% CI, 0.98 ~ 1.08), P-Value = 0.21 更多 | - | 2018-11-01 | ||
No finasteride use prior to prostate cancer diagnosis |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用